Drug Disposition Issues in CKD: Implications for Drug Discovery and Regulatory Approval

Area of Science:

• Pharmacology
• Nephrology
• Drug Metabolism

Background:

• Patients with chronic kidney disease (CKD) frequently have comorbidities like hypertension, diabetes, anemia, and cardiovascular disease.
• Advanced CKD patients, particularly those on hemodialysis, use numerous medications (average 12), increasing the risk of adverse drug events.
• Altered drug clearance (renal and nonrenal) in CKD is a key factor contributing to these adverse events.

Purpose of the Study:

• To review pharmacokinetic considerations in patients with chronic kidney disease.
• To examine Food and Drug Administration (FDA) guidelines for pharmacokinetic studies in CKD.
• To outline collaborative roles in enhancing drug safety for CKD patients.

Main Methods:

• Literature review of pharmacokinetic alterations in CKD.
• Analysis of FDA guidance documents on drug studies in CKD populations.
• Discussion of interdisciplinary responsibilities for drug safety.

Main Results:

• Altered drug pharmacokinetics in CKD necessitates careful medication management.
• Existing FDA guidelines provide a framework for studying drug behavior in CKD.
• Collaboration among academia, industry, and regulatory bodies is crucial for progress.

Conclusions:

• Understanding pharmacokinetic changes in CKD is vital for mitigating adverse drug events.
• Adherence to and refinement of FDA guidelines can improve drug development for CKD patients.
• A coordinated approach is essential to ensure the safe and effective use of medications in this vulnerable population.